外周血免疫表型监测CAR19揭示组织学特异性扩增与毒性
该前瞻性队列研究纳入236例接受CAR19(brexucabtagene autoleucel或axicabtagene ciloleucel)治疗的套细胞淋巴瘤、滤泡性淋巴瘤和大B细胞淋巴瘤患者,对其中188例通过外周血免疫表型获取CAR19扩增数据。CAR19扩增在套细胞淋巴瘤中高于其他组织学亚型,且与细胞因子释放综合征、免疫效应细胞相关神经毒性综合征及输注后14天需粒细胞集落刺激因子相关。
要点
- 套细胞淋巴瘤患者的CAR19扩增高于其他淋巴瘤组织学亚型。
- 套细胞淋巴瘤患者毒性增加,所需累积类固醇剂量为LBCL患者的四倍。
- CAR19扩增主要与CAR相关毒性相关,在LBCL中可能并非有利结局所必需。
核心结论
- CAR19扩增主要与CAR相关毒性相关;通过外周血免疫表型测得的CAR19扩增对于LBCL的有利结局可能并非必需。
研究设计与样本
- 前瞻性随访5年的队列研究,纳入236例接受CAR19(brexucabtagene autoleucel或axicabtagene ciloleucel)治疗的套细胞淋巴瘤、滤泡性淋巴瘤和大B细胞淋巴瘤患者,其中188例获得外周血免疫表型CAR19扩增数据。
主要发现
- 套细胞淋巴瘤患者的CAR19扩增高于其他淋巴瘤组织学亚型。
- 套细胞淋巴瘤患者毒性增加,所需累积类固醇剂量为LBCL患者的四倍。
- CAR19扩增与细胞因子释放综合征、免疫效应细胞相关神经毒性综合征及输注后14天需粒细胞集落刺激因子相关。
- 年轻患者和乳酸脱氢酶升高患者的CAR19扩增显著更高。
- 总体上未观察到CAR19扩增与LBCL治疗反应之间的关联;在控制肿瘤负荷后,较低的CAR19扩增合并低乳酸脱氢酶与LBCL结局改善相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells directed against CD19 (CAR19) are a revolutionary treatment for B-cell lymphomas (BCLs). CAR19 cell expansion is necessary for CAR19 function but is also associated with toxicity. To define the impact of CAR19 expansion on patient outcomes, we prospectively followed a cohort of 236 patients treated with CAR19 (brexucabtagene autoleucel or axicabtagene ciloleucel) for mantle cell lymphoma (MCL), follicular lymphoma, and large BCL (LBCL) over the course of 5 years and obtained CAR19 expansion data using peripheral blood immunophenotyping for 188 of these patients. CAR19 expansion was higher in patients with MCL than other lymphoma histologic subtypes. Notably, patients with MCL had increased toxicity and required fourfold higher cumulative steroid doses than patients with LBCL. CAR19 expansion was associated with the development of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and the requirement for granulocyte colony-stimulating factor 14 days after infusion. Younger patients and those with elevated lactate dehydrogenase (LDH) had significantly higher CAR19 expansion. In general, no association between CAR19 expansion and LBCL treatment response was observed. However, when controlling for tumor burden, we found that lower CAR19 expansion in conjunction with low LDH was associated with improved outcomes in LBCL. In sum, this study finds CAR19 expansion principally associates with CAR-related toxicity. Additionally, CAR19 expansion as measured by peripheral blood immunophenotyping may be dispensable to favorable outcomes in LBCL.
引用
- Hamilton MP, Craig E, Gentille Sanchez C, et al. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. 2024. PMID: 38498731. doi:10.1182/bloodadvances.2024012637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。